Skip to main content
. 2023 Sep 22;26(5):480. doi: 10.3892/ol.2023.14060

Figure 6.

Figure 6.

Clinical utility of combined GIS and BRCA1/2 analysis in ovarian cancer. The diagram shows the increase in the HRD detection obtained by the combination of BRCA1/2 and GIS analysis. GIS, genomic instability score; HRD, homologous recombination deficiency; NGS, next-generation sequencing; BRCA1/2+, BRCA1 or BRCA2 positive patients; BRCA1/2-, BRCA1 or BRCA2 negative patients; BRCA1/2-GIS+, GIS positive cases and BRCA1/2 negative cases; BRCA1/2-GIS-, GIS and BRCA1/2 negative cases.